8.56
price up icon3.65%   0.34
 
loading
전일 마감가:
$8.22
열려 있는:
$8.57
하루 거래량:
7,353
Relative Volume:
0.01
시가총액:
$327.40M
수익:
$127.70M
순이익/손실:
$-121.25M
주가수익비율:
-2.7175
EPS:
-3.15
순현금흐름:
$-120.32M
1주 성능:
+9.03%
1개월 성능:
+16.64%
6개월 성능:
+4.45%
1년 성능:
-51.34%
1일 변동 폭
Value
$8.52
$8.57
1주일 범위
Value
$7.73
$8.745
52주 변동 폭
Value
$4.80
$18.13

아이테오스 Stock (ITOS) Company Profile

Name
명칭
Iteos Therapeutics Inc
Name
전화
857-204-4583
Name
주소
321 ARSENAL STREET, WATERTOWN
Name
직원
173
Name
트위터
Name
다음 수익 날짜
2024-11-05
Name
최신 SEC 제출 서류
Name
ITOS's Discussions on Twitter

ITOS을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
ITOS
Iteos Therapeutics Inc
8.555 305.04M 127.70M -121.25M -120.32M -3.15
Biotechnology icon
ONC
Beigene Ltd Adr
238.76 24.41B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
434.03 111.55B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.2548 42.47M 0 0 0 0.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
596.85 63.16B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
VRNA
Verona Pharma Plc Adr
72.69 5.92B 0 -153.72M -103.81M -2.00

아이테오스 Stock (ITOS) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-05-14 다운그레이드 H.C. Wainwright Buy → Neutral
2025-05-14 다운그레이드 Leerink Partners Outperform → Market Perform
2025-05-13 다운그레이드 JP Morgan Overweight → Neutral
2024-08-13 개시 Wells Fargo Overweight
2021-05-05 개시 H.C. Wainwright Buy
2020-10-08 개시 Robert W. Baird Outperform
2020-08-18 개시 JP Morgan Overweight
2020-08-18 개시 Piper Sandler Overweight
2020-08-18 개시 SVB Leerink Outperform
2020-08-18 개시 Wedbush Outperform
모두보기

아이테오스 주식(ITOS)의 최신 뉴스

pulisher
May 19, 2025

Balyasny Asset Management L.P. Buys Shares of 28,350 iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World

May 19, 2025
pulisher
May 19, 2025

Q2 Earnings Forecast for ITOS Issued By Leerink Partnrs - Defense World

May 19, 2025
pulisher
May 18, 2025

Q4 Earnings Forecast for ITOS Issued By Leerink Partnrs - Defense World

May 18, 2025
pulisher
May 18, 2025

The week in pharma: action, reaction and insight – week to May 16 - The Pharma Letter

May 18, 2025
pulisher
May 18, 2025

Wall Street Analysts Think iTeos Therapeutics (ITOS) Could Surge 212.5%: Read This Before Placing a Bet - MSN

May 18, 2025
pulisher
May 17, 2025

Research Analysts Issue Forecasts for ITOS Q2 Earnings - Defense World

May 17, 2025
pulisher
May 17, 2025

iTeos Therapeutics, Inc. (NASDAQ:ITOS) Receives $18.83 Average Target Price from Analysts - Defense World

May 17, 2025
pulisher
May 16, 2025

iTeos Therapeutics (NASDAQ:ITOS) Rating Lowered to “Hold” at Leerink Partnrs - Defense World

May 16, 2025
pulisher
May 16, 2025

Leerink Partners Reiterates “Market Perform” Rating for iTeos Therapeutics (NASDAQ:ITOS) - Defense World

May 16, 2025
pulisher
May 15, 2025

ITOS: ITeos Therapeutics Downgraded to Neutral by HC Wainwright & Co. | ITOS Stock News - GuruFocus

May 15, 2025
pulisher
May 14, 2025

iTeos Therapeutics: End To Belrestotug Program Leads To A Hold Rating (NASDAQ:ITOS) - Seeking Alpha

May 14, 2025
pulisher
May 14, 2025

Piper Sandler cuts iTeos stock price target to $12 from $16 - Investing.com Canada

May 14, 2025
pulisher
May 14, 2025

ITeos Therapeutics (ITOS) Sees Price Target Adjustment by Piper Sandler | ITOS Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

iTeos, GSK End Collaboration On Experimental Cancer Therapy Development: But Retail’s Extremely Bullish - NewsBreak: Local News & Alerts

May 14, 2025
pulisher
May 14, 2025

ITeos Therapeutics (ITOS): Analyst Lowers Price Target, Rating R - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Strategic Shift and Strong Financials Position iTeos Therapeutics for Growth - TipRanks

May 14, 2025
pulisher
May 14, 2025

ITeos Therapeutics (ITOS) Downgraded by Leerink Partners | ITOS Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

This Wayfair Analyst Turns Bearish; Here Are Top 4 Downgrades For Wednesday - Benzinga

May 14, 2025
pulisher
May 14, 2025

Leerink Downgrades iTeos Therapeutics to Market Perform From Outperform - marketscreener.com

May 14, 2025
pulisher
May 14, 2025

HC Wainwright Downgrades iTeos Therapeutics to Neutral From Buy - marketscreener.com

May 14, 2025
pulisher
May 14, 2025

iTeos Therapeutics (ITOS) Receives Adjusted Price Target from We - GuruFocus

May 14, 2025
pulisher
May 14, 2025

iTeos Therapeutics (ITOS) Receives Adjusted Price Target from Wells Fargo | ITOS Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

iTeos Therapeutics (ITOS) Faces Downgrade Following GSK's Decisi - GuruFocus

May 14, 2025
pulisher
May 14, 2025

GSK (GSK) and iTeos Halt Belrestotug Development After Disappoin - GuruFocus

May 14, 2025
pulisher
May 14, 2025

iTeos Therapeutics price target lowered to $12 from $16 at Piper Sandler - TipRanks

May 14, 2025
pulisher
May 14, 2025

iTeos Therapeutics (ITOS) Faces Downgrade Following GSK's Decision | ITOS Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

GSK (GSK) and iTeos Halt Belrestotug Development After Disappointing Trial Results | GSK Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

iTeos Therapeutics (ITOS) Downgraded by Analyst with New Price T - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Leerink downgrades iTeos Therapeutics after termination of TIGIT program - TipRanks

May 14, 2025
pulisher
May 14, 2025

iTeos and GSK halt lung cancer drug development By Investing.com - Investing.com India

May 14, 2025
pulisher
May 14, 2025

GSK, partner iTeos end development programme for lung cancer drug belrestotug - Medical Dialogues

May 14, 2025
pulisher
May 14, 2025

ITeos Therapeutics (ITOS) Downgraded by JP Morgan | ITOS Stock N - GuruFocus

May 14, 2025
pulisher
May 13, 2025

As iTeos, GSK shelve belrestotug, prospects for TIGIT continue to dim - BioCentury

May 13, 2025
pulisher
May 13, 2025

iTeos Therapeutics: TIGIT Falls, And A Zombie Rises? (NASDAQ:ITOS) - Seeking Alpha

May 13, 2025
pulisher
May 13, 2025

iTeos/GSK To Terminate Collaboration After TIGIT Trials Flop - insights.citeline.com

May 13, 2025
pulisher
May 13, 2025

JPMorgan cuts iTeos Therapeutics stock rating to neutral, target to $8 - Investing.com Australia

May 13, 2025
pulisher
May 13, 2025

GSK and iTeos end belrestotug antibody program By Investing.com - Investing.com Nigeria

May 13, 2025
pulisher
May 13, 2025

JPMorgan cuts iTeos Therapeutics stock rating to neutral, target to $8 By Investing.com - Investing.com Nigeria

May 13, 2025
pulisher
May 13, 2025

iTeos Therapeutics (ITOS) Downgraded by JPMorgan Analyst | ITOS Stock News - GuruFocus

May 13, 2025
pulisher
May 13, 2025

GSK, partner iTeos scrap development of lung cancer therapy - NewsBreak: Local News & Alerts

May 13, 2025
pulisher
May 13, 2025

iTeos Stock Soars Despite Trial Setback On Liquidation Buzz And Solid Cash Pile - Yahoo Finance

May 13, 2025
pulisher
May 13, 2025

iTeos and GSK to drop belrestotug + dostarlimab collaboration - The Pharma Letter

May 13, 2025
pulisher
May 13, 2025

iTeos Reports Topline Interim Results from GALAXIES Lung-201 Stu - GuruFocus

May 13, 2025
pulisher
May 13, 2025

iTeos, GSK to shelve TIGIT drug after study setback - BioPharma Dive

May 13, 2025
pulisher
May 13, 2025

ITeos Terminates TIGIT Program After Phase 2 Lung Study Misses PFS Endpoint, Explores Options - Nasdaq

May 13, 2025
pulisher
May 13, 2025

ITeos, GSK discontinue lung cancer therapy development - KFGO

May 13, 2025
pulisher
May 13, 2025

Wedbush Adjusts Price Target on iTeos Therapeutics to $10 From $25, Maintains Outperform Rating - marketscreener.com

May 13, 2025
pulisher
May 13, 2025

GSK (GSK) and iTeos Halt Development of Lung Cancer Drug Combo - GuruFocus

May 13, 2025
pulisher
May 13, 2025

GSK, iTeos Therapeutics End Belrestotug Development Program - marketscreener.com

May 13, 2025
pulisher
May 13, 2025

iTeos stock rises despite clinical trial setback By Investing.com - Investing.com South Africa

May 13, 2025
pulisher
May 13, 2025

iTeos stock rises despite clinical trial setback - Investing.com Australia

May 13, 2025

아이테오스 (ITOS) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$581.44
price down icon 0.60%
$1.39
price down icon 6.15%
$32.50
price down icon 0.28%
$289.00
price down icon 1.22%
$4.2299
price up icon 5.48%
$72.69
price down icon 1.89%
자본화:     |  볼륨(24시간):